Stock Details
BMY is Bristol-Myers Squibb Company's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 75.52$. Average daily volumn in 3 months 15.21M. Market cap 162.11B



Stock symbol : BMY. Exchange : NYSE. Currency : USD
Lastest price : 76.14$. Total volume : 16.32M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Bristol-Myers Squibb Company (BMY)
Last Price
76.14$
Change
-1.45
Volume
16.32M

Previous Close77.59
Open77.31
Day Range75.46-77.44
Bid76.25 x 1.8k
Ask76.35 x 800
Volume16.32M
Average Volume15.21M
Market Cap162.11B
Beta0.48
52 Week Range53.22-78.61
Trailing P/E26.97
Foward P/E9.37
Dividend (Yield %)2.78%
Ex-Dividend Date2022-03-31



Financial Details


According to Bristol-Myers Squibb Company's financial reports the company's revenue in 2021 were 46.38B an increase( +9.52%) over the years 2020 revenue that were of 42.52B. In 2021 the company's total earnings were 6.99B while total earnings in 2020 were -9.02B(-166.67%).


Loading ...



Organization

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indi... cations; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Market Cap:
162.11B
Revenue:
46.38B
Total Assets:
109.31B
Total Cash:
13.98B


News about "Bristol-Myers Squibb Company"

bristol-myers-squibb-a-safe-spot-for-a-worrisome-investor-image

Bristol Myers Squibb: A Safe Spot For A Worrisome Investor

Source from : Seeking Alpha - 13 hours ago

Bristol Myers Squibb's new products will likely mitigate risk of generic competitors. See why I believe applying a Buy rating is appropriate for BMY stock now.See details»


Bristol Myers Squibb Says FDA Approves Two Opdivo-Based Regimens

Source from : MarketWatch - 22 hours ago

By Stephen Nakrosis Bristol Myers Squibb Co. on Friday said the U.S. Food and Drug Administration approved a pair of Opdivo-based regimens to treat ...See details»


citigroup-increases-bristol-myers-squibb-nysebmy-price-target-to-9000-image

Citigroup Increases Bristol-Myers Squibb (NYSE:BMY) Price Target to $90.00

Source from : Defense World - 2 days ago

Bristol-Myers Squibb (NYSE:BMY – Get Rating) had its price objective boosted by equities researchers at Citigroup from $75.00 to $90.00 in a research note issued on Thursday, The Fly reports.See details»


Bristol Myers Squibb announces positive results from phase 2 PILOT study of Breyanzi to treat refractory or relapsed LBCL after first-line therapy

Source from : Pharmabiz - 13 hours ago

Bristol Myers Squibb announces positive results from phase 2 PILOT study of Breyanzi to treat refractory or relapsed LBCL after first-line therapy: Princeton, New Jersey Saturday, ...See details»


edp-renewables-and-bristol-myers-squibb-execute-power-purchase-agreement-for-the-cattlemen-solar-park-image

EDP Renewables and Bristol Myers Squibb Execute Power Purchase Agreement for the Cattlemen Solar Park

Source from : YAHOO!Finance - 5 days ago

Long-term agreement will enable the continued development and eventual construction and operation of the Texas solar park that will annually power the equivalent of more than 37,000 average homes ...See details»


Bristol-Myers Squibb Company (BMY): This Stock is set to Soar Above its Peers

Source from : investchronicle - 5 days ago

Let’s start up with the current stock price of Bristol-Myers Squibb Company (BMY), which is $76.19 to be very precise. The Stock rose vividly during the last session to $77.15 after opening rate of ...See details»


top-stock-reports-for-tesla-procter-gamble-bristol-myers-squibb-image

Top Stock Reports for Tesla, Procter & Gamble & Bristol-Myers Squibb

Source from : YAHOO!Finance - 2 days ago

Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), The Procter & Gamble Company (PG), and Bristol-Myers Squibb Company (BMY).See details»


bristol-myers-squibb-a-safe-haven-in-times-of-uncertainty-image

Bristol-Myers Squibb: A Safe Haven In Times Of Uncertainty

Source from : Seeking Alpha - 7 days ago

Geopolitics and risk of economic recession in the U.S. is forcing investors to look for defensive stocks. Here's why I'm bullish on BMY shares.See details»


analyzing-bristol-myers-squibbs-short-interest-image

Analyzing Bristol-Myers Squibb's Short Interest

Source from : Benzinga.com - 5 days ago

Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 10.76% since its last report. The company recently reported that it has 42.24 million shares sold short, ...See details»


Bristol-Myers Squibb (NYSE:BMY) Sees Large Decline in Short Interest

Source from : Defense World - 11 days ago

Bristol-Myers Squibb (NYSE:BMY – Get Rating) was the target of a significant decrease in short interest in the month of April. As of April 30th, there was short interest totalling 35,370,000 shares, a ...See details»


The Zacks Analyst Blog Highlights Tesla, Procter & Gamble, Bristol-Myers Squibb, Wells Fargo and Intuit

Source from : Nasdaq - 1 days ago

(You can read the full research report on Procter & Gamble here >>>) Shares of Bristol-Myers Squibb have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+21.3% vs ...See details»


The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More

Source from : Business Insider - 6 days ago

Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support.See details»


Bristol Myers Squibb: Phase 3 CheckMate -901 Trial Fails To Meet Primary Endpoint

Source from : Nasdaq - 12 days ago

Bristol Myers Squibb (BMY) said the phase 3 CheckMate -901 trial, comparing Opdivo plus Yervoy to standard-of-care chemotherapy as a first-line treatment for patients with untreated unresectable or ...See details»


sap-sapphire-2022-how-bristol-myers-squibb-uses-sap-btp-to-evolve-their-s4hana-landscape-and-their-business-image

SAP Sapphire 2022 - How Bristol Myers Squibb uses SAP BTP to evolve their S/4HANA landscape - and their business

Source from : Diginomica - 10 days ago

So I asked Michael Di Novi of Bristol Myers Squibb something I know nothing about: how do you work for the same company for 30 years? You earn your way into meaty new roles, that's how. Di Novi, now ...See details»